相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma
Enrico Derenzini et al.
HAEMATOLOGICA (2021)
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Nikita Kotlov et al.
CANCER DISCOVERY (2021)
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL
Annette M. Staiger et al.
LEUKEMIA (2020)
Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study
Christopher R. Bolen et al.
HAEMATOLOGICA (2020)
A 70% cut-off for MYC protein expression in diffuse large B-cell lymphoma identifies a high-risk group of patients
Marita Ziepert et al.
HAEMATOLOGICA (2020)
TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma
Daisuke Ennishi et al.
NATURE MEDICINE (2020)
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report
Stuart E. Lacy et al.
BLOOD (2020)
DLBCL subclassification: divide and conquer?
Ryan D. Morin et al.
BLOOD (2020)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Evolutionary crossroads: morphological heterogeneity reflects divergent intra-clonal evolution in a case of high-grade B-cell lymphoma
Valentina Tabanelli et al.
HAEMATOLOGICA (2020)
A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas
Claudio Tripodo et al.
ISCIENCE (2020)
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
Daisuke Ennishi et al.
CANCER DISCOVERY (2019)
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies et al.
LANCET ONCOLOGY (2019)
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
David M. Kurtz et al.
CELL (2019)
ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP (R2 -CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
U. Vitolo et al.
HEMATOLOGICAL ONCOLOGY (2019)
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Daisuke Ennishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Using Gene Expression Profiling to Move Beyond MYC/BCL2 Rearrangements in High-Grade Lymphoma
Wing C. Chan
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy
Chulin Sha et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens
Anja Mottok et al.
BLOOD (2018)
Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue
S. Ciavarella et al.
ANNALS OF ONCOLOGY (2018)
Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts
Grace Gifford et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay
Jean-Philippe Jais et al.
HAEMATOLOGICA (2017)
Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group
Annette M. Staiger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Umberto Vitolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay
Jean-Philippe Jais et al.
HAEMATOLOGICA (2017)
Significance of stromal-1 and stromal-2 signatures and biologic prognostic model in diffuse large B-cell lymphoma
Asmaa Gaber Abdou et al.
CANCER BIOLOGY & MEDICINE (2017)
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma
Anupama Reddy et al.
CELL (2017)
Diffuse large B-cell lymphoma genotyping on the liquid biopsy
Davide Rossi et al.
BLOOD (2017)
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
Florian Scherer et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
David W. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
David W. Scott et al.
BLOOD (2014)
Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma
Rong Bu et al.
LEUKEMIA & LYMPHOMA (2014)
CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy
Colm Keane et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu et al.
BLOOD (2013)
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu-Monette et al.
BLOOD (2012)
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Marie Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
C. Visco et al.
LEUKEMIA (2012)
The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
Paul N. Meyer et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
Gonzalo Gutierrez-Garcia et al.
BLOOD (2011)
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment
Ash A. Alizadeh et al.
BLOOD (2011)
Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
Paul N. Meyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
William W. L. Choi et al.
CLINICAL CANCER RESEARCH (2009)
Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
Heidi Nyman et al.
MODERN PATHOLOGY (2009)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenburg Lymphoma Biomarker Consortium
Daphne de Jong et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Aberrant NF-kappa B signaling in lymphoma: mechanisms, consequences, and therapeutic implications
Philipp J. Jost et al.
BLOOD (2007)
Immunohistochemical profiling based on Bcl-2, CD10 and MUMI expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma
JJF Muris et al.
JOURNAL OF PATHOLOGY (2006)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
G Wright et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma
L Colomo et al.
BLOOD (2003)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
分享论文
